|
|
|
|
|
|
|
PEER-TO-PEER CLINICAL CONVERSATIONS |
|
|
|
|
|
|
Racial Differences in Bladder Cancer Detection Using Blue Light Cystoscopy: A Multi-Center Study
|
|
Siamak Daneshmand, MD
|
| Ashish Kamat and Siamak Daneshmand discuss research on racial differences in tumor detection using blue light cystoscopy. The study reveals that while blue light enhances tumor detection universally, there are notable variations among racial groups, with Asian patients benefiting significantly.
|
|
|
|
|
|
|
|
|
|
|
|
| Patient Burdens and Openness to In-Home Intravesical Therapy for Bladder Cancer |
Amanda Myers, MD, and Timothy Lyon, MD
Sam Chang hosts Amanda Myers and Tim Lyon to discuss the burdens of intravesical therapy for bladder cancer. Dr. Myers shares insights from their study on the patient-reported treatment burdens, revealing significant challenges related to travel, cost, and daily life disruptions due to the current clinic-based treatment setup.
|
|
|
|
|
|
|
|
|
|
|
|
Disparities and Underutilization of Aggressive Therapy in Muscle-Invasive Bladder Cancer: An NCDB Analysis
|
|
James E. Ferguson III, MD, PhD
|
| Sam Chang is joined by James (Jed) Ferguson to explore disparities in the treatment of muscle-invasive bladder cancer. Dr. Ferguson's team delved into the National Cancer Database, revealing that a significant percentage of patients do not receive aggressive treatments post-TURBT, with factors such as age, comorbidity, race, insurance status, and treatment facility type playing crucial roles in the variance of care.
|
|
|
|
|
|
|
|
|
|
|
|
|
Urban vs Rural Bladder Cancer Mortality: 20-Year Trend Analysis
|
|
Jason Brown, MD, PhD
|
| Sam Chang interviews Jason Brown about research on disparities in bladder cancer mortality between urban and rural settings from 2000 to 2020. Dr. Brown highlights a significant decline in urban mortality, particularly in large metropolitan areas, while rural rates remain stagnant, with a more pronounced urban improvement post-2016 following immunotherapy approvals.
|
|
|
|
|
|
|
|
|
|
|
|
| Identifying Genetic Determinants and Vulnerabilities of Histologic Variants of Bladder Cancer |
| John Lee, MD, PhD |
| John Lee presents research on identifying genetic determinants and vulnerabilities in histologic variants of bladder cancer. His team's innovative combinatorial genetic strategy utilizes organoid transformation assays and barcoded lentiviral libraries to create diverse bladder cancer models, enabling the study of polygenic drivers of tumor phenotypes. |
|
|
|
|
|
| Identifying Individual and Community-Level Drivers of Disparities in Bladder Cancer Clinical Trials Participation |
| Rishi Sekar, MD |
| Rishi Sekar presents his research on the disparities in bladder cancer clinical trial participation driven by individual and community-level factors. Dr. Sekar’s findings indicate that social determinants of health significantly affect clinical trial awareness and participation, revealing that socially vulnerable patients have markedly lower rates of trial discussion and involvement, underscoring the need for enhanced clinical trial access in these communities to improve cancer care equity. |
|
|
|
|
|
| Using Molecular Testing to Guide Perioperative Systemic Therapy for Urothelial Cancer |
| Matt Galsky, MD |
| Matt Galsky discussed the potential of molecular testing, particularly circulating tumor DNA (ctDNA), to enhance perioperative systemic therapy for urothelial cancer. He highlighted the challenges of identifying which patients need treatment and who benefits, noting that ctDNA can serve as a biomarker for both prognosis and treatment efficacy. |
|
|
|
|
|
|
|
|
|
|
Digital Spatial Profiling in Muscle-Invasive Bladder Cancer - Expert Commentary
|
| Bishoy Faltas, MD |
| Bishoy Faltas discusses a recent study by Eyers et al. explored the application of digital spatial profiling (DSP) in muscle-invasive bladder cancer (MIBC), emphasizing its capability to capture spatially relevant information often missed in bulk molecular analyses. Utilizing archival formalin-fixed, paraffin-embedded (FFPE) samples from 34 patients, the researchers employed the GeoMx platform with a Whole Transcriptome Atlas panel comprising over 18,000 RNA probes. |
|
|
|
|
|
| Stool Microbiome Signature Associated with Response to Neoadjuvant Pembrolizumab in Patients with Muscle-Invasive Bladder Cancer - Beyond the Abstract
|
| Filippo Pederzoli, MD, PhD, Andrea Necchi, MD, Massimo Alfano, PhD
|
| The recent study detailed by Pederzoli et al. highlights the significant role of the gut microbiome in influencing the efficacy of immunotherapy for muscle-invasive bladder cancer (MIBC). Specifically, it focuses on the impact of the microbiome on patient response to neoadjuvant treatment with pembrolizumab, a PD-1 inhibitor, within the context of the PURE-01 clinical trial.
|
|
|
|
|
|
|
|
|
|
|
